Glucagon-like peptide-1 (GLP-1) receptor agonists, a newly developed category of medications for diabetes management, have demonstrated potential cardioprotective, nephroprotective, and also neuroprotective effects in individuals with T2DM. This evidence concerns the gene GLP1R and diabetes mellitus.